Drug
Ertugliflozin clinical trials
Also written MK-8835, PF-04971729 and Steglatro.
- studies test it
- 37
- open now
- 5
- in phase 3
- 14
- first study started
- 2009
Keep track of what changes. Save the ertugliflozin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2010 (6)
| Year | Studies |
|---|---|
| 2009 | 2 |
| 2010 | 6 |
| 2013 | 6 |
| 2014 | 4 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 2 |
| 2023 | 4 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 4
- Phase 3
- 14
- Phase 4
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 15
Merck Sharp & Dohme LLC (20) · Amsterdam UMC, location VUmc (3) · Stanford University (1) · Icahn School of Medicine at Mount Sinai (1) · Humanis Saglık Anonim Sirketi (1) · University Health Network, Toronto (1) · Asan Medical Center (1) · Soo Lim (1)
Often tested with
Tested in the same studies.
Sitagliptin (2) · Metformin (1) · Finerenone (1) · Semaglutide (1) · Benazepril (1) · Captopril (1) · Enalapril (1) · Fosinopril (1)
Studies
Open first, then newest update. How each study uses ertugliflozin is read from its arms, and is right about nine times in ten.
Testing it · 37
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878Written as Ertugliflozin
- Ertugliflozin's Effect on Heart Function in Diabetic Patients After Myocardial InfarctionNot yet recruitingPhase 4Shanghai Zhongshan HospitalNCT07621380Written as Ertugliflozin 10 mg
- Ertugliflozin in Chronic Heart FailureRecruitingPhase 2Yale UniversityNCT04438213Written as Ertugliflozin
- DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study, a Randomized, Placebo-controlled, Cross-over Study With Ertugliflozin in People With Type 2 DiabetesRecruitingPhase 4Amsterdam UMC, location VUmcNCT06983054Written as ertugliflozine
- Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLDRecruitingPhase 4Getz PharmaNCT05644717Written as Ertugliflozin 5 mg, 15mg
- Ertugliflozin: Cardioprotective Effects on Epicardial FatCompletedEarly Phase 1Stanford UniversityNCT04167761Written as Ertugliflozin
- ERTU-SODIUM: Study on the Effects of Ertugliflozin on Sodium Storage, Interstitial Volume, and Plasma Volume in HFrEFCompletedPhase 4Icahn School of Medicine at Mount SinaiNCT05152940Written as Ertugliflozin
- DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN StudyCompletedPhase 4Amsterdam UMC, location VUmcNCT05727579Written as Ertugliflozin 15 mg
- Bioequivalence Study of Test Product (T) of Ertugliflozin/Metformin 7.5 mg/ 1000 mg Film Coated Tablets and Reference Product (R) of Segluromet 7.5 mg/ 1000 mg Film Coated Tablets in Healthy, Adult, Human Subjects Under Fed Condition.CompletedPhase 1Humanis Saglık Anonim SirketiNCT07266779Written as Ertugliflozin/Metformin film coated tablets
- Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)CompletedPhase 3Merck Sharp & Dohme LLCNCT04029480Written as Ertugliflozin 5 mg
- Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III StudyTerminatedPhase 3Medical University of GrazNCT04600921Written as Ertugliflozin 5 mg
- ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart FailureCompletedPhase 2University Health Network, TorontoNCT03416270Written as Ertugliflozin
- Ertugliflozin for Functional Mitral RegurgitationCompletedPhase 3Asan Medical CenterNCT04231331Written as Ertugliflozin
- Effect of Ertugliflozin on Cardiac Function in DiabetesCompletedPhase 3Soo LimNCT03717194Written as Ertugliflozin
- Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart FailureTerminatedPhase 4University Hospitals Cleveland Medical CenterNCT04071626Written as Ertugliflozin 5 mg
- Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.CompletedPhase 4Amsterdam UMC, location VUmcNCT04027530Written as Ertugliflozin 15 mg
- Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)CompletedPhase 3Merck Sharp & Dohme LLCNCT01986881Written as Ertugliflozin
- Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL)Status unknownPhase 3Yonsei UniversityNCT04490681Written as Ertugliflozin
- A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)CompletedPhase 1Merck Sharp & Dohme LLCNCT01018823Written as Ertugliflozin
- A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)CompletedPhase 1Merck Sharp & Dohme LLCNCT00989079Written as Ertugliflozin
Codes
What other systems call ertugliflozin · ClinicalTrials.gg INT005995
- MeSH (NLM) C570288ertugliflozinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6C282481IPERTUGLIFLOZINConfirmed FDA, NLM, Wikidata
- RxNorm 1992672Confirmed FDA, Wikidata
- Wikidata Q27077223ertugliflozinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166925ErtugliflozinOne source FDA
- DrugBank DB11827One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C570288 | ertugliflozin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6C282481IP | ERTUGLIFLOZIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1992672 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27077223 | ertugliflozin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166925 | Ertugliflozin | One source FDA |
| DrugBank | DB11827 | — | One source Wikidata |
Also registered as ertugliflozin pidolate (UNII MLU731K321 · RxNorm 1992674).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.